Achondroplasia Treatment Market

1. Coherent Market Insights Market Research and Business Consulting Services https://www.coherentmarketinsights.com/ COVID-19 Impact Tracker

2. ACHONDROPLASIA TREATMENT MARKET ANALYSIS Achondroplasia Treatment Market, By Drug Class (Lipase Inhibitor, Human Growth Hormone And Appetite Suppressants), By Distribution Channel (Hospitals Pharmacies, Speciality Clinics, Online Pharmacy, And Retail Pharmacy), By Patient Type (Adult And Paediatric), And By Region (North America, Latin America, Europe, Asia Pacific, Middle East, And Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

3. Market Drivers • Achondroplasia is a rare disease which can be treated in various ways such as surgical treatment, hormone therapy, ongoing health care and limb lengthening. Therefore, pharmaceutical companies are focusing on product development in treatment of achondroplasia. For instance, in July 2020, BioMarin Pharmaceutical Inc. submitted a marketing authorization application to the European Medical Agency for vosoritide, an injection of c-type natriuretic peptide for treatment of achondroplasia. These factors are expected to drive growth of the global achondroplasia treatment market. Furthermore, pharmaceutical companies are focusing on research and development of treatments for achondroplasia. For instance, in June 2020, Biomarin Pharmaceuticals entered phase II clinical trials of evaluating safety, tolerability and efficacy of BMN III (Vosoritide)  in treating children with achondroplasia.

4. Global Achondroplasia Treatment Market: COVID-19 Impact Analysis Since the outbreak of the COVID-19 pandemic, several markets across the globe have been affected negatively. Pharmaceutical companies operating in this market are facing challenges in carrying out clinical trials due to concerns regarding safety and wellbeing of participants. Furthermore, safety precautions which have been imposed to curb spread of the COVID-19 infection have created complications in carrying out surgical treatments and hormone therapy for achondroplasia.

5. Market Restraints • Cost of the growth hormone therapy ranges from US$ 10,000 to US$ 60,000 depending upon the amount of hormone used for the treatment; therefore, growth hormone therapy is expensive for individuals in low- and mid-income countries. Moreover, growth hormone therapy is characterised by side effects such as carpal tunnel syndrome, higher insulin resistance and heightened risk of developing cancer. These factors are expected to restrain global achondroplasia treatment market growth.

6. Market Regional Analysis • . On the basis of regions, the global achondroplasia treatment market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. According to National Library of Medicine 2018 report, prevalence of achondroplasia in North America is 0.3 to 0.6 out of 10,000 individuals. Moreover, North America has various social associations such as Association of Little People of Alberto (ALPA) and Dwarf Athletic Association of Canada (DAAC) which offer health support and emotional support to patients with achondroplasia. Furthermore, pharmaceutical companies are focusing on strategies such mergers and acquisitions to innovate potential treatments for achondroplasia.

7. Market Regional Analysis • In Europe, prevalence of achondroplasia is significantly more than other regions. According to the European Commission, in 2019, prevalence of achondroplasia was 3.67 per 10,000 births in the region. Therefore, pharmaceutical companies are focusing on research and development of treatments for achondroplasia to strengthen their share in the global anchondroplasia treatment market. For instance, in August 2020, AcendicPharma A/S, a pharmaceutical company, received an orphan drug designation for Transcon, a c-type natriuretic peptide for treatment of achondroplasia from the European Commission.

8. Key Players • Key operating players in global achondroplasia treatment market are AscendisPharma A/S, BridgeBioPharma, Inc., QED Therapeutics, BioMarin Pharmaceutical Inc., Pfizer Inc., Therachon Holding AG and RIBOMIC Inc. • Market Taxonomy: • On the basis of drug class, the global achondroplasia treatment market is segmented into: • Lipase Inhibitor • Appetite Suppresants • Human Growth Hormone

9. Key Players • On the basis of distribution channel, the global achondroplasia treatment market is segmented into: • Hospital Pharmacies • Online Pharmacy • Retail Pharmacy • On the basis of patient type, the global achondroplasia treatment market is segmented into: • Adult • Paediatric

10. Key Players • On the basis of region, the global achondroplasia treatment market is segmented into: • North America • Latin America • Europe • Asia Pacific • Middle East • Africa

11. Request Sample Report • Request Customization • Download PDF Brochure • Talk to Analyst • Buy Now Reference:https://www.coherentmarketinsights.com/ongoing-insight/achondroplasia-treatment-market-4161

12. About Us Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. What we provide: • Customized Market Research Services • Industry Analysis Services • Business Consulting Services • Market Intelligence Services • Long term Engagement Model • Country Specific Analysis

13. Contact Us Mr. Shah Coherent Market Insights Pvt.Ltd. Address: 1001 4th Ave, #3200 Seattle, WA 98154, U.S. Phone: +1-206-701-6702 Email: sales@coherentmarketinsights.com

14. Thank You! Kindly follow CMI Social Media Profiles for the latest company updates Facebook Linkedin Twitter https://www.coherentmarketinsights.com/